Contacare Ophthalmics AND Diagnostics Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Contacare Ophthalmics AND Diagnostics Pharmaceutical Export Portfolio Dataset — 2 Products, $2.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Contacare Ophthalmics AND Diagnostics — Pharmaceutical Exporter Profile (2026) | 2 Products, $2.4M Trade | TransData Nexus

Contacare Ophthalmics AND Diagnostics

Indian Pharmaceutical Exporter · Medical Devices & Diagnostics Specialist · $2.4M Total Trade · DGFT Verified

Contacare Ophthalmics AND Diagnostics is an Indian pharmaceutical exporter with a total trade value of $2.4M across 2 products in 1 therapeutic categories. Based on 398 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Syringe ($1.9M), Strip ($510.3K), .

Contacare Ophthalmics AND Diagnostics — Export Portfolio & Destination Treemap

Contacare Ophthalmics AND Diagnostics pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Contacare Ophthalmics AND Diagnostics? — Company Overview & Market Position

Contacare Ophthalmics and Diagnostics, established in 1996, is a prominent Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, particularly in the ophthalmic sector. The company is headquartered in Vadodara, Gujarat, India, with its manufacturing facilities located in Padra, Gujarat. Contacare operates as a 100% Export Oriented Unit (EOU), focusing on the production and export of ophthalmic products.

The company's ownership structure is not publicly disclosed. Contacare is registered under the Corporate Identification Number (CIN) 24AAACC6606P1ZJ, indicating its legal standing in India. While specific revenue figures are not publicly available, the company employs approximately 100 individuals, reflecting its scale and operational capacity.

What Does Contacare Ophthalmics AND Diagnostics Export? — Product Portfolio Analysis

Top Products by Export Value

1Syringe$1.9M 2Strip

Product Portfolio — Top 2 by Export Value

Contacare Ophthalmics AND Diagnostics exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Syringe	Medical Devices & Diagnostics	$1.9M	290	1.1%	9
2	Strip	Medical Devices & Diagnostics	$510.3K	108	0.3%	15

Contacare Ophthalmics AND Diagnostics exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $2.4M. The top category is Medical Devices & Diagnostics (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Contacare Ophthalmics AND Diagnostics — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Contacare's manufacturing facilities are situated in Padra, Gujarat, India. The company operates as a 100% Export Oriented Unit (EOU), focusing on the production and export of ophthalmic products. Specific details regarding the capacities and specializations of these facilities are not publicly disclosed.

3Key Leadership

The company's leadership includes Mr. Biswa Ranjan Pradhan, who serves as the Director. Other key executives, such as the CEO, CFO, and additional members of the leadership team, are not publicly disclosed.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Contacare Ophthalmics AND Diagnostics Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Contacare has engaged in trade with the United States, as evidenced by shipments to companies like Beaver Visitec International Inc. in 2019. However, the company has faced regulatory challenges in the U.S. market. In August 2017, the FDA issued Import Alert 55-05, which applied to all aseptically processed drugs manufactured or shipped by Contacare, including Sodium Chloride ophthalmic solution. Additionally, in April 2019, the FDA issued a Warning Letter to Contacare, citing violations related to sterility assurance and quality control.

In the European Union, United Kingdom, Australia, and Japan, specific regulatory filings, approvals, and market access statuses for Contacare are not publicly available. The company's focus appears to be primarily on the U.S. market, with limited information regarding its presence in these regions.

2Emerging Markets

Contacare's export activities have extended to regions such as South America, with shipments to countries like the United States and South American nations. However, specific details regarding the company's presence in Africa, Latin America, and Southeast Asia are not publicly disclosed. The company's focus on ophthalmic products suggests potential opportunities in emerging markets, but further information is limited.

Geographic Strategy

Contacare Ophthalmics AND Diagnostics — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Contacare's manufacturing facility in Padra, Gujarat, India, is registered with the FDA, as indicated by its Facility Establishment Identifier (FEI) number 3006217304. The company has faced regulatory challenges in the U.S. market, including an Import Alert issued by the FDA in August 2017, which applied to all aseptically processed drugs manufactured or shipped by Contacare. Additionally, in April 2019, the FDA issued a Warning Letter to Contacare, citing violations related to sterility assurance and quality control. These actions highlight the importance of addressing regulatory compliance to maintain market access.

2WHO & EU GMP

Specific information regarding Contacare's compliance with WHO prequalification, EU GMP certificates, and EDQM status is not publicly available. The company's focus on the U.S. market and the limited availability of information suggest that it may not hold these certifications. Obtaining such certifications could enhance the company's credibility and facilitate entry into additional regulated markets.

3CDSCO & Indian Regulatory

Contacare Ophthalmics AND Diagnostics — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Contacare operates in the ophthalmic pharmaceutical sector, competing with other manufacturers of contact lenses, intraocular lenses, and related diagnostic products. Specific market share data and a detailed head-to-head analysis are not publicly available. However, the company's focus on ophthalmic products positions it within a competitive market that includes both domestic and international players.

2Key Differentiators

Contacare's specialization in ophthalmic products, including contact lenses and intraocular lenses, distinguishes it in the pharmaceutical export market. The company's commitment to precision and daily comfort for users reflects its focus on quality and patient satisfaction. However, the limited diversification in its product portfolio, with the top five products accounting for 100% of exports, suggests a need for broader product offerings to mitigate market risks.

3Strategic Position

Contacare's current strategic direction appears to be focused on the export of ophthalmic products, primarily to the U.S. market. The company's portfolio concentration indicates a specialized approach, but the limited diversification may expose it to market fluctuations. Future strategic initiatives could include obtaining WHO prequalification and EU GMP certifications to enhance credibility and facilitate entry into additional regulated markets.

Buyer Due Diligence Brief — Evaluating Contacare Ophthalmics AND Diagnostics as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Contacare has demonstrated a consistent export volume, with 398 shipments totaling $2.4 million USD. The company's focus on ophthalmic products and its specialization in this sector reflect a reliable track record in its niche market. However, the limited diversification in its product portfolio suggests a need for broader offerings to enhance reliability and reduce dependency on a narrow product range.

2Certifications to Verify

Importers should verify the following certifications when considering Contacare as a supplier:

FDA Registration: Confirm the facility's registration status with the FDA to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify the company's adherence to World Health Organization Good Manufacturing Practices to ensure product quality and safety.

EU GMP Certification: Ensure the company holds European Union Good Manufacturing Practices certification for access to European markets.

Frequently Asked Questions — Contacare Ophthalmics AND Diagnostics

How many pharmaceutical products does Contacare Ophthalmics AND Diagnostics export from India?

Contacare Ophthalmics AND Diagnostics exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Syringe ($1.9M), Strip ($510.3K). Total export value is $2.4M.

What is Contacare Ophthalmics AND Diagnostics's total pharmaceutical export value?

Contacare Ophthalmics AND Diagnostics's total pharmaceutical export value is $2.4M, based on 398 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Contacare Ophthalmics AND Diagnostics cover?

Contacare Ophthalmics AND Diagnostics exports across 1 therapeutic categories. The largest are Medical Devices & Diagnostics (100.0%, 2 products).

Get Full Contacare Ophthalmics AND Diagnostics Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.